Yahoo Finance • last year
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold... Full story
Yahoo Finance • last year
– Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada’s transition to a clinical-stage company – – Expanded the Company’s Duchenne franchise with the selection of i... Full story
Yahoo Finance • last year
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-thera... Full story
Yahoo Finance • 2 years ago
- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutic... Full story
Yahoo Finance • 2 years ago
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a n... Full story
Yahoo Finance • 2 years ago
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a n... Full story
Yahoo Finance • 2 years ago
SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis i... Full story
Yahoo Finance • 2 years ago
- Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 - - Actively working to resolve the clinical hold on its IND application fo... Full story
Yahoo Finance • 2 years ago
BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular therapeutics company by establishing End... Full story
Yahoo Finance • 2 years ago
- Global collaboration includes ENTR-701, Entrada’s late-stage preclinical candidate for the treatment of DM1 - - Company’s cash runway extended into the second half of 2025 - BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeut... Full story
Yahoo Finance • 2 years ago
NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA). Such investors are advised to contact Robert S. Willoughb... Full story
Yahoo Finance • 2 years ago
NEW YORK, Jan. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. (“Entrada” or the “Company”) (NASDAQ: TRDA). Such investors are advised to contact Robert S. Willoug... Full story
Yahoo Finance • 2 years ago
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a ne... Full story
Yahoo Finance • 2 years ago
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a ne... Full story
Yahoo Finance • 2 years ago
Shares of Entrada Therapeutics Inc. rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. that aims to develop treatments for myotonic dystrophy type 1, a genetic disorder that cau... Full story
Yahoo Finance • 2 years ago
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping amenable in the fourth quart... Full story
Yahoo Finance • 2 years ago
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a ne... Full story
Yahoo Finance • 2 years ago
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 Cash runway into 2H 2024 with $244 million in cash, cash equivalents and mar... Full story
Yahoo Finance • 2 years ago
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome measures and endpoints for clinical trials... Full story
Yahoo Finance • 2 years ago
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a ne... Full story